“The role of circulating tumor cells (CTCs) in drug discovery and development is growing and full of potential as new technologies are enabling us to use CTCs for the first time as templates for novel DNA, RNA and protein biomarkers. Together with our collaborators we are in the forefront of work to develop a next-generation system that will enable CTCs to be used both by oncologists as a diagnostic tools for personalizing patient care, as well as by research to accelerate and improve the process of drug discovery and development.”
Dr. Nicholas Dracopoli brings extensive experience in the fields of genomics, molecular biology and cancer research to his role as Vice President and Head of Oncology Biomarkers at Janssen Research & Development, where he leads the teams responsible for biomarker discovery, development and application for oncology therapeutics and companion diagnostics. Previously, he was Vice President of Clinical Discovery Technologies at another leading pharmaceutical company, and prior to that spent five years in the biotechnology industry.
Dr. Dracopoli obtained his B.Sc. and Ph.D. degrees from the University of London, and completed post-doctoral fellowships at the Memorial Sloan-Kettering Cancer Center and the Massachusetts Institute of Technology (MIT). Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center, and as a Section Chief at National Cancer for Human Genome Research at the NIH, before moving to the biotechnology industry.